Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xylitol + glucose + l-carnitine
- Development stage
- Unknown
- Lead developer
- Iperboreal Pharma
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
A combination solution of xylitol, glucose, and L-carnitine is being developed as an innovative peritoneal dialysis (PD) fluid for patients with end-stage renal disease (ESRD). This formulation aims to reduce the intraperitoneal glucose load by partially replacing glucose with osmo-metabolic agents—xylitol and L-carnitine—which possess both osmotic and favorable metabolic properties. The mechanism involves using these agents as alternative osmolytes to maintain ultrafiltration while mitigating the negative systemic metabolic effects associated with high-glucose PD solutions. Clinical studies suggest that this approach may improve insulin sensitivity, glycemic control, and biocompatibility of the PD fluid without compromising efficacy or safety. The product is under investigation in clinical trials such as ELIXIR (using the brand name Xylocore), which evaluates its potential to reduce glucose exposure-related toxicities in PD patients[1][2][3][5].
- Brand names
- Xylocore
- Other names
- peritoneal dialysis solution containing combination of D-xylitol, D-glucose, L-carnitine
02
Targets
SLC7A1 (Cationic amino acid transporter 1)
Beyond the preview
Go deeper on xylitol + glucose + l-carnitine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xylitol + glucose + l-carnitine.